Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCITECT: Botensilimab and Balstilimab in Advanced Renal Cell Cancer
NCT05928806Phase 2Suspended
- Start
- Sep 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab, balstilimab in renal cell carcinoma (RCC). Started Sep 2023; status: suspended.
02
Drugs
botensilimabbalstilimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05928806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928806.